Ubs Oconnor LLC Neurocrine Biosciences Inc Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 30,000 shares of NBIX stock, worth $3.69 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

30,000

Holding current value

$3.69 Million

% of portfolio

0.24%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $1.76 Million - $2.35 Million	15,370 Added 94.29%	31,670 $3.65 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $300,978 - $329,337	2,300 Added 16.43%	16,300 $2.24 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $755,798 - $833,117	-5,796 Reduced 29.28%	14,000 $1.93 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $1.49 Million - $1.86 Million	-14,002 Reduced 41.43%	19,796 $2.61 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $470,100 - $585,500	-5,000 Reduced 12.89%	33,798 $3.8 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $3.47 Million - $4.07 Million	38,798 New	38,798 $3.66 Billion
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $2.38 Million - $3.11 Million	25,242 Added 424.95%	31,182 $3.16 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $1.18 Million - $1.41 Million	-11,063 Reduced 65.06%	5,940 $0
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $1.86 Million - $2.18 Million	-20,200 Reduced 54.3%	17,003 $1.81 Billion
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $924,865 - $1.22 Million	12,203 Added 48.81%	37,203 $3.63 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $1.81 Million - $2.37 Million	25,000 New	25,000 $2.34 Million

Others Institutions Holding NBIX

# of Institutions

616

Shares Held

94.2M

Call Options Held

557K

Put Options Held

545K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account